Has alopecia areata entered the era of precision medicine? Experts discuss the future of biomarkers, clinical trials, patient outcomes, stigma, and remaining unmet needs in dermatology.
...
Discover the science behind alopecia areata as experts challenge misconceptions about genetics, nutritional deficiencies, nail involvement, and predicting disease severity.
Alopecia areata is more than hair loss. Dermatologists discuss mental health, quality of life, shared decision-making, and the hidden burden of this autoimmune disease.
Are there effective treatments for alopecia areata? Experts debunk myths about JAK inhibitors, steroids, treatment success, relapse, and managing severe or longstanding disease.
Can stress really cause alopecia areata? Does hair regrowth mean the disease is cured? This expert discussion separates fact from fiction, debunking some of the most common myths.
In a comparison of the mental health of patients with acne treated with isotretinoin vs oral antibiotics, which treatment group was found to experience more depressive symptoms and psychological distress?
In a comparison of the mental health of patients with acne treated with isotretinoin vs oral antibiotics, which treatment group was found to experience more depressive symptoms and psychological distress?
Climbing the mountain to get to dermatology residency is bone breaking enough, but what about the next apex, even more specialized training such as a Dermatopathology Fellowship?
Climbing the mountain to get to dermatology residency is bone breaking enough, but what about the next apex, even more specialized training such as a Dermatopathology Fellowship?
Gain practical insights on improving diagnostic accuracy, minimizing unnecessary interventions, and refining patient-centered strategies for melanoma screening in daily practice.
Gain practical insights on improving diagnostic accuracy, minimizing unnecessary interventions, and refining patient-centered strategies for melanoma screening in daily practice.
Dr Brian S. Kim unpacks the latest breakthroughs in the neuroimmunology of itch, revealing how innovative targeted treatments are transforming our approach to chronic itch and reshaping dermatologic care.
Dr Brian S. Kim unpacks the latest breakthroughs in the neuroimmunology of itch, revealing how innovative targeted treatments are transforming our approach to chronic itch and reshaping dermatologic care.
What proportion of children aged 6 to 11 years with severe atopic dermatitis receiving dupilumab achieved a height increase of at least 5 percentile points after 4 months of treatment?
What proportion of children aged 6 to 11 years with severe atopic dermatitis receiving dupilumab achieved a height increase of at least 5 percentile points after 4 months of treatment?
Evaluate advanced clinical reasoning in targeted treatment selection, unexpected therapeutic responses, and the challenges of precision medicine in inflammatory dermatology.
Evaluate advanced clinical reasoning in targeted treatment selection, unexpected therapeutic responses, and the challenges of precision medicine in inflammatory dermatology.
Challenge your understanding of inflammatory feedback mechanisms, neuronal sensitization, and the complex cellular interactions involved in chronic dermatologic disease.
Challenge your understanding of inflammatory feedback mechanisms, neuronal sensitization, and the complex cellular interactions involved in chronic dermatologic disease.
Test your clinical understanding of inflammatory disease classification, overlapping immune pathways, and the evolving role of type 2 inflammation in dermatology.
Test your clinical understanding of inflammatory disease classification, overlapping immune pathways, and the evolving role of type 2 inflammation in dermatology.
Challenge your understanding of treatment sequencing, biologic failure, JAK inhibitor escalation, and future biomarker-driven approaches in inflammatory dermatology.
Challenge your understanding of treatment sequencing, biologic failure, JAK inhibitor escalation, and future biomarker-driven approaches in inflammatory dermatology.
Evaluate your clinical approach to selecting targeted therapies across multiple type 2 inflammatory skin diseases by integrating disease biology, symptom burden, and treatment sequencing.
Evaluate your clinical approach to selecting targeted therapies across multiple type 2 inflammatory skin diseases by integrating disease biology, symptom burden, and treatment sequencing.
Which of the following best describes the week 12 efficacy findings for povorcitinib in the phase 3 STOP-HS1 and STOP-HS2 trials in patients with moderate-to-severe hidradenitis suppurativa?
Which of the following best describes the week 12 efficacy findings for povorcitinib in the phase 3 STOP-HS1 and STOP-HS2 trials in patients with moderate-to-severe hidradenitis suppurativa?
Evaluate your understanding of disease fluctuation, neuroimmune signaling, cytokine biology, and targeted therapeutic strategies in chronic spontaneous urticaria.
Evaluate your understanding of disease fluctuation, neuroimmune signaling, cytokine biology, and targeted therapeutic strategies in chronic spontaneous urticaria.
Test your understanding of cytokine signaling, mast cell biology, neuroimmune interactions, and the mechanisms that drive chronic spontaneous urticaria.
Test your understanding of cytokine signaling, mast cell biology, neuroimmune interactions, and the mechanisms that drive chronic spontaneous urticaria.
